This expanded feasibility agreement builds upon the successful completion of a previous research study between the parties. Scope and terms of the agreement were not disclosed.
Ray Salemme, CEO of Redpoint Bio, said: “We are extremely pleased to have expanded our research collaboration with Schering. We believe this agreement is a further endorsement of Redpoint Bio’s unique taste science platform and it’s applicability to pharmaceutical development. We look forward to continuing our good working relationship with the Schering team.”